Medacta Expands its Knee Offerings with New SensiTiN System with Low Metal Ion Release
CASTEL SAN PIETRO, 19 October 2020 - Medacta announced today the official launch of the new SensiTiN system in the European market. This system includes titanium niobium nitride (TiNbN) coated knee implants for use in total knee replacement and revision procedures.
Medacta SensiTiN system has been designed to reduce metal ion release. Leveraging the clinical experience gained in Europe with GMK Sphere and GMK Primary TiNbN coated implants, Medacta has decided to extend this technology to its revision system (GMK Hinge SensiTiN and GMK Revision SensiTiN) for which it has recently received the CE marking. Following this important registration, the SensiTiN system is now a complete system that allows for treating a larger number of patients, from primary to complex revision cases. Moreover, the system will become even more complete with the upcoming introduction of the Medacta TiNbN coated partial knee system.
Pieter Ackerman, M.D., has recently performed a surgery utilizing a GMK Hinge SensiTiN at Az Sint-Vincentius Hospital in Deinze, Belgium. 'I am very excited about the new SensiTiN system, as it dramatically reduces the exposure of patients to metallic ions,' said Dr. Ackerman. 'As the most advanced technique to limit the release of ions in total knee replacement, the titanium niobium nitride coating minimizes the risk of adverse reactions, especially for patients with proven or suspected sensitivity to metal ions.'
The SensiTiN system has now been extended to the entire GMK family for total knee replacement (from GMK Primary to GMK Revision and Hinge), retaining all the features of the Medacta GMK system. The GMK system includes versatile and comprehensive knee arthroplasty solutions designed to preserve joint functionality. The GMK instrumentation is designed to minimize complexity. Thanks to its modularity, the surgeon is able to better adapt their approach to different surgical scenarios.
Medacta provides surgeons with continuous support in the application of its knee portfolio and other products through the M.O.R.E. Institute, which offers comprehensive educational programs that aim to help surgeons get their patients back to their healthy and active lifestyles as safely and efficiently as possible.
Learn more about Medacta's knee portfolio at knee.medacta.com.
Medacta International SA
Senior Director Global Marketing
Phone: +41 91 696 60 60
Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated MySolutions technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.